Shares in the company rose more than 35% on the strength of the data, which could put DBV on track to bring the immunotherapy to market in the US as the first alternative to Stallergenes Greer's ...

DBV Technologies (DBVT) stock climbs as a Phase 3 trial for its Viaskin Peanut patch for peanut allergy in children succeeds. Read more here.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...

Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...

With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 ...

DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash. The disclosure came via a going concern note in the company’s fourth-quarter and full-year ...

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced positive twenty-four month results from its Open-Label ...

In 2020, the FDA refused to approve DBV Technologies lead candidate, the Viaskin Peanut patch, citing adhesion issues. DBV enlarged the patch and had intended to try again without running a new phase ...

DBV announced that the FDA lifted a partial clinical hold on its phase 3 study of DBV712. The product is a patch intended for use in kids with peanut allergies. The FDA placed DBV Technologies' phase ...

DBV Technologies has withdrawn the filing for FDA approval of its peanut allergy therapy. The French biotech pulled the BLA after talks with the agency revealed gaps in the manufacturing and ...

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years DBV Technologies (Euronext: DBV – ISIN: ...